KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients - Concepedia

Concepedia

Publication | Open Access

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

DOI Full Paper Access

28

Citations

21

References

2012

Year

Michele Basso, Antonia Strippoli, Armando Orlandi, Maurizio Martini, Maria Alessandra Calegari, Giovanni Schinzari, Mariantonietta Di Salvatore, Tonia Cenci, Alessandra Cassano, Luigi Maria Larocca,

British Journal of Cancer

Abstract

Our results suggest that activating mutation of KRAS oncogene may predict response to OXA. Basal expression of ERCC-1 mRNA does not explain the high efficacy of FOLFOX-6 in mt KRAS patients.

References

	Year	Citations

Page 1